fda compounding semaglutide enforcement news november 2025 is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger to protect patients from unverified Chinese companies turn to generics

Sources Innerbody uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles

During the procedure, parafilm was placed under the vessels to prevent capsaicin exposure to any other adjacent visceral tissues

GLP-1 Therapies and Risk of Muscle Loss Glucagon-like peptide-1 (GLP-1) medications have increasingly been prescribed to treat cardiometabolic conditions such as obesity, diabetes, and cardiovascular diseasesYeo et al (2024) conducted a nationwide analysis on the usage of GLP-1's in patients without diabetes and observed a 700% (from 21,000 in 2019 to 174,000 in 2023) increase between the years 2019-2023

All compounded weight management therapies are prepared in response to a licensed healthcare providers prescription and are created specifically for one individual patient

More importantly, the weight loss caused by tirzepatide in these animals likely contributed to adverse outcomes independently of the drug itself